Transcription of EGFR-TKI 標靶治療藥品用於晚期及轉移性非小細胞肺癌 －療 …
{{id}} {{{paragraph}}}
Example: stock market
EGFR-TKI 標靶治療藥品用於晚期及轉移性非小細胞肺癌 －療 …
EGFR-TKI .. 1, 2.. 2015 2 101 . 2010 . [1] . (small cell lung cancer) (non-small cell lung cancer, NSCLC) . 13% 87% . Stage IIIb . (advanced NSCLC) 40% Stage IV (metastatic NSCLC) [2-6] .. III IIIb . IV .. (performace status, PS) .. [2, 6] .. cisplatin carboplatin . 1.. 2.. RegMed 2015 Vol. 61 20. etoposide mitomycin ifosfamide topotecan irinotecan paclitaxel . docetaxel vinblastine vinorelbine gemcitabine pemetrexed . (platinum-based doublets) carboplatin/paclitaxel, cisplatin/docetaxel, cisplatin/paclitaxel, cisplatin/gemcitabine, cisplatin/vinorelbine, cisplatin/irinotecan [6] .. egfr KRAS ALK PIK3CA . BRAF HER2 p161NK4a p53 (molecular-targeted therapy) (monoclonal antibodies) . (small molecule inhibitors) tyrosine kinase inhibitors, TKIs [3, 6-7] .. (1) VEGF bevacizumab (2) ALK ALK . [ 1] ALK-TKI crizotinib ceritinib (3). egfr EGFR-TKI [ 2] gefitinib, erlotinib afatinib . cetuximab cetuximab . egfr (overexpression) 40-80% [4, 6-10] . EGFR-TKI .
RegMed 2015 Vol. 61 23 已有結果發表之LUX-lung 8 試驗及Kim et al.試驗皆是針對第二線治療進行 EGFR-TKI 療效的直接比較，兩項試驗皆未特別針對EGFR 突變進行病人篩選[註8]。其中
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: